Xeris Biopharma Holdings Stock (NASDAQ: XERS)

Xeris Biopharma Holdings (NASDAQ:XERS) Stock, Quote.Headers.trade-ideas

Xeris Biopharma Holdings

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BFLY

LWAY

SKYH

SPNS

XERS

Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Penny stock: gli insider muovono il mercato con acquisti strategici

Long Ideas

Penny Stocks

Insider Trades

BCOV

PGEN

More Than $20M Bet On Precigen? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying

STKS

Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings Inc

Earnings

Guidance

Retail Sales

General

Foot Locker Expects Q4 2024 Sales To Decline Between 3.5% To 1.5%, With Comparable Sales Of +1.5% To +3.5%

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.

Price Target

Reiteration

Analyst Ratings

RYTM

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

Barclays analyst Raimo Lenschow maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Overweight and raises the price target from $415 to $425.

Barclays Maintains Overweight on Salesforce, Raises Price Target to $425

Lowering 2024 Sales and Non-GAAP EPS Outlook
The Company's full year 2024 outlook, representing the 52 weeks ending February 1, 2025, is summarized in the table below.&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Metric</td>
<td colspan="1" rowspan="1">Prior Full Year&nbsp; Guidance</td>
<td colspan="1" rowspan="1">Updated Full Year&nbsp; Guidance</td>
<td colspan="1" rowspan="1">Fourth Quarter&nbsp; Guidance</td>
<td colspan="1" rowspan="1">Commentary</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sales Change</td>
<td colspan="1" rowspan="1">-1.0% to +1.0%</td>
<td colspan="1" rowspan="1">-1.5% to -1.0%</td>
<td colspan="1" rowspan="1">-3.5% to -1.5%</td>
<td colspan="1" rowspan="1">~$100 million headwind from 53rd week in 2023</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Comparable Sales Change</td>
<td colspan="1" rowspan="1">+1.0% to +3.0%</td>
<td colspan="1" rowspan="1">+1.0% to +1.5%</td>
<td colspan="1" rowspan="1">+1.5% to +3.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Store Count Change</td>
<td colspan="1" rowspan="1">Down ~4%</td>
<td colspan="1" rowspan="1">Down ~4%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Square Footage Change</td>
<td colspan="1" rowspan="1">Down ~2%</td>
<td colspan="1" rowspan="1">Down ~2%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Licensing Revenue</td>
<td colspan="1" rowspan="1">~$17 million</td>
<td colspan="1" rowspan="1">~$16 million</td>
<td colspan="1" rowspan="1">~$4 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">29.5% to 29.7%</td>
<td colspan="1" rowspan="1">28.7% to 28.8%</td>
<td colspan="1" rowspan="1">29.0% to 29.2%</td>
<td colspan="1" rowspan="1">Promotional pressure</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SG&amp;A Rate</td>
<td colspan="1" rowspan="1">24.1% to 24.3%</td>
<td colspan="1" rowspan="1">24.0% to 24.1%</td>
<td colspan="1" rowspan="1">22.3% to 22.5%</td>
<td colspan="1" rowspan="1">Investment spending</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">D&amp;A</td>
<td colspan="1" rowspan="1">$210 to $215 million</td>
<td colspan="1" rowspan="1">~$203 million</td>
<td colspan="1" rowspan="1">~$50 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EBIT Margin</td>
<td colspan="1" rowspan="1">2.8% to 3.2%</td>
<td colspan="1" rowspan="1">2.3% to 2.5%</td>
<td colspan="1" rowspan="1">4.5% to 5.0%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Interest</td>
<td colspan="1" rowspan="1">~$10 million</td>
<td colspan="1" rowspan="1">~$8 million</td>
<td colspan="1" rowspan="1">~$2 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Tax Rate</td>
<td colspan="1" rowspan="1">33.0% to 34.0%</td>
<td colspan="1" rowspan="1">~34.0%</td>
<td colspan="1" rowspan="1">33.0% to 34.0%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP EPS</td>
<td colspan="1" rowspan="1">$1.50 to $1.70</td>
<td colspan="1" rowspan="1">$1.20 to $1.30</td>
<td colspan="1" rowspan="1">$0.70 to $0.80</td>
<td colspan="1" rowspan="1">Includes $0.09 drag from non-recurring FLX charge in 2Q</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital Expenditures</td>
<td colspan="1" rowspan="1">$275 million</td>
<td colspan="1" rowspan="1">$270 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. Capital Expenditures&#x2A;</td>
<td colspan="1" rowspan="1">$330 million</td>
<td colspan="1" rowspan="1">$320 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Includes ~$50 million in technology investment reflected in operating cash flows</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Foot Locker Expects 2024 Sales To Decline Between 1.5% To 1.0%, Compared To Prior Guidance Of -1.0% To +1.0%, With Comparable Sales Growth Of +1.0% To +1.5% Vs. Prior Guidance Of +1.0% To +3.0%

Barclays analyst Andrew Mok maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Overweight and raises the price target from $79 to $85.

RDNT

Barclays Maintains Overweight on RadNet, Raises Price Target to $85

Foot Locker Reports Q3 Comparable Sales Up 2.4%

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) with a Buy and maintains $3 price target.

OVID

HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target

Barclays analyst Tim Long maintains Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) with a Equal-Weight and raises the price target from $56 to $61.

PSTG

Barclays Maintains Equal-Weight on Pure Storage, Raises Price Target to $61

VINC

Vincerx Pharma Announced Plans To Implement Cost-controls And Explore Strategic Alternatives To Support Advancing The Phase 1 Study Of VIP943, The Company's Novel CD123-targeted Antibody-drug Conjugate (ADC) Developed With The Company's Next-generation VersAptx Platform

Keefe, Bruyette &amp; Woods analyst Catherine Mealor upgrades Shore Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHBI#NASDAQ">SHBI</a>) from Market Perform to Outperform and raises the price target from $16 to $20.

Upgrades

SHBI

Keefe, Bruyette & Woods Upgrades Shore Bancshares to Outperform, Raises Price Target to $20

Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $0.41 by 19.51 percent. The company reported quarterly sales of $1.96 billion which missed the analyst consensus estimate of $2.01 billion by 2.82 percent. This is a 1.56 percent decrease over sales of $1.99 billion the same period last year.

Foot Locker Q3 2024 Adj EPS $0.33 Misses $0.41 Estimate, Sales $1.96B Miss $2.01B Estimate

Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy and maintains $4 price target.

HRTX

Needham Reiterates Buy on Heron Therapeutics, Maintains $4 Price Target

It would seem that optimists currently see no reason to abandon their bullishness, with the benchmark S&amp;P 500 index again<a href="https://www.benzinga.com/news/earnings/24/12/42308304/sp-500-hits-another-high-as-apple-tops-242-for-the-first-time-fear-index-remains-in-greed-zone"> inking another record close</a>. What's more, the available data appears to justify an acquisitive posture. For example, job openings rose by 372,000 to 7.744 million in October, up from a revised reading of 7.372 million in the prior month. The latest figure also beat analysts' consensus view of 7.48 million.
So far this year, the venerable index has<a href="https://www.benzinga.com/markets/24/12/42309028/sp-500s-record-breaking-streak-in-2024-could-signal-caution-for-investors-in-2025-warn-analysts-stocks-do-not-go-up-forever"> printed 54 all-time highs</a>. In addition to labor market dynamics, the jump in the S&amp;P 500 can be attributed to Federal Reserve rate cuts, excitement over artificial intelligence and President-elect Donald Trump's pro-market policies. Nevertheless, analysts at Ned Davis Research sounded the alarm: the stunning rally may represent too much of a good thing.
"Historical data since 1928 shows that in years when the S&amp;P 500 hit more than 35 record highs, the median gain for the index the following year was a mere 5.8%, falling short of the long-term average of 8%," wrote Benzinga's Navdeep Yadav when covering the news. "In years with at least 50 record highs, the median return was -6% the following year."
Naturally, the concern is that "stocks do not go up forever," analysts quoted in the article remarked, adding that "Perhaps AI will drive another productivity and profit boom that will keep inflation and Fed policy benign. History suggests that is the exception rather than the rule."
To be fair, some notable exceptions exist, such as in 1996, when the benchmark index returned 20% despite inking 77 record highs the previous year. Still, the quoted strategists are quick to point out that these gains stemmed from the dot-com era's productivity spike.
Another warning to consider is the technical framework. While it's easy to celebrate the bull market, the bulk of the equity arena's returns hailed from only a handful of enterprises. "Continued narrowing would set the stock market up for a tougher 2025," the analysts warned.
The Direxion ETF: Investors who have similarly grown skeptical of the market's seemingly relentless march higher can exercise their contrarianism with the Direxion Daily S&amp;P 500 Bear 1X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPDN#NYSE">SPDN</a>). As the financial services provider states on its website, the SPDN is an exchange-traded fund that seeks 100% of the inverse (or opposite) performance of the namesake index.
A key advantage of the S&amp;P 500 bear fund is convenience. SPDN can be acquired in a similar vein to picking up a security. Therefore, investors don't need to participate in the options market, which may add a layer of complexity. However, it's important that traders do not hold their position for longer than one day. Otherwise, the effect of leverage compounding in an inverse fund can lead to value erosion.
The SPDN Chart: To no surprise, the SPDN ETF has been a poor performer this year, losing over 19% of its value since the beginning of January. Still, a possible turnaround has the potential to lead to significant upside.
<ul>
<li>Currently, the inverse fund is struggling against a decisively declining trend channel, punctuated with a price action below key moving averages.</li>
<li>At the same time, while the S&amp;P 500 index has climbed higher, the law of large numbers may be stymieing its progress.</li>
<li>Ideally, SPDN bulls (or market bears) will be looking for a baseline at or above the $10.50 mark, which may signal a sentiment reversal.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="810" height="450" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04064529/image.jpeg" alt="" class="wp-image-676197" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04064529/image.jpeg 810w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04064529/image-300x167.jpeg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/04064529/image-768x427.jpeg 768w" sizes="(max-width: 810px) 100vw, 810px" /></figure>
Featured photo by <a href="https://pixabay.com/users/ambquinn-4464111/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7591629">Angela</a> on <a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7591629">Pixabay</a>.

Short Ideas

Technicals

ETFs

SPDN

Skeptical Contrarians May Find Opportunity In Direxion's S&P 500 Bear Fund

DLTR

Dollar Tree Revises FY24 Consolidated Net Sales Outlook Range From $30.6B - $30.9B To $30.7B - $30.9B (Est $30.727B), Adjusted EPS Outlook From $5.20 - $5.60 To $5.31 - $5.51 (Est $5.38)

On December 3, 2024, the Board of Directors declared regular dividends on the various series of first preferred shares and a dividend of $1.14 per common share, up 4 cents or 4%, payable on February 1, 2025 to shareholders of record on December 30, 2024.&nbsp;

Dividends

NTIOF

National Bank of Canada Raised Quarterly Dividend By 4% To C$1.14/Share

Barclays analyst Saket Kalia maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Equal-Weight and raises the price target from $81 to $96.

OKTA

Barclays Maintains Equal-Weight on Okta, Raises Price Target to $96

Goldman Sachs analyst Mark Delaney maintains Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Neutral and lowers the price target from $34 to $28.

Goldman Sachs Maintains Neutral on Symbotic, Lowers Price Target to $28

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Buy and raises the price target from $41 to $45.

RNAC

HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Raises Price Target to $45

Barclays analyst Blayne Curtis maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Overweight and raises the price target from $85 to $115.

MRVL

Barclays Maintains Overweight on Marvell Tech, Raises Price Target to $115

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report). The co...

Xeris Pharmaceuticals (XERS) Gets a Buy from Craig-Hallum

Xeris Pharmaceuticals Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Xeris Pharmaceuticals GAAP EPS of -$0.11 misses by $0.02, revenue of $54.3M beats by $2.87M

Stock Picks From Seeking Alpha's October 2024 New Analysts

Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript

Xeris Pharmaceuticals ( ($XERS) ) has released its Q3 earnings. Here is a breakdown of the information Xeris Pharmaceuticals presented to its inves...

Xeris Biopharma Reports Record Third Quarter Revenue

Piper Sandler analyst David Amsellem downgraded the rating on Xeris Pharmaceuticals (XERS – Research Report) to a Hold yesterday, setting a price t...

Xeris Pharmaceuticals: Hold Rating Amid Growth and Cost Concerns

Piper Sandler analyst David Amsellem downgraded Xeris Biopharma (XERS) to Neutral from Overweight with an unchanged price target of $3, post the Q3...

Xeris Biopharma downgraded to Neutral from Overweight at Piper Sandler

Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) on November 8 and set a price target...

Xeris Pharmaceuticals: Strong Financial Performance and Strategic Growth Drive Buy Rating

ACGL

ACGLN

ACGLO

ADNT

AMCX

AMPS

AMRX

ANIP

APOG

ASOMF

ASOMY

ATSG

ATZAF

AVRE

BEPC

BHPLF

BILL

BLMN

BWXT

CBWTF

CIVI

CIVII

CIVIW

CONY

CRLBF

CRMD

CSGP

DCBO

DGEAF

DOCMF

DRMTY

FLGT

FSLR

HRTG

HUMA

ICAGY

IFRX

ILLMF

JNPR

JVTSF

LAMR

LOTBY

MSTR

OCGN

OPINL

PAGP

PARAA

PSEC

QTRHF

RCMT

REGCO

REGCP

SONY

TALK

TALKW

TGHLF

TMCWW

TSMWF

VRTX

Press Releases

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Announces CEO Succession Plan

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Xeris to Participate in Upcoming Investor Conferences

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Comments

Xeris Biopharma Holdings

Xeris Biopharma Holdings (XERS) Forecast

Xeris Biopharma Holdings (NASDAQ:XERS) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga